Charm Therapeutics Soars with $80M for AML Drug Development
Charm Therapeutics has closed an $80 million oversubscribed Series B, co-led by NEA and SR One, to advance its...
Jon Napitupulu
Pharming Group Appoints Kenneth Lynard as New CFO
Pharming Group has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, adding a seasoned finance operator...
Wegovy Cuts Heart Attack, Stroke Risk 57% vs. Tirzepatide
Novo Nordisk unveiled new real-world evidence at ESC 2025 suggesting that Wegovy (semaglutide 2.4 mg) is associated with a...
Spotlight on Biomerica’s Fiscal 2025 Year-End Results
Biomerica reported fiscal 2025 results with revenue essentially flat at $5.3 million and a narrowed operating loss of $5.1...
FDA Approves Leqembi Subcutaneous Injection for Alzheimer’s
FDA has approved Eisai and Biogen’s Leqembi iqlik, a once-weekly 360 mg subcutaneous autoinjector for maintenance dosing after 18...
Hernexeos® Approved in China for HER2-Mutant Lung Cancer
Boehringer Ingelheim has secured accelerated approval in China for HERNEXEOS (zongertinib) as monotherapy for adults with unresectable, locally advanced,...
OMass, Genentech Secure Exclusive IBD Therapy Agreement
Genentech has entered an exclusive collaboration and license agreement with OMass Therapeutics for a preclinical oral small molecule program...
Charm’s Successful $80M Round Fuels AML Drug Development
Charm Therapeutics has closed an oversubscribed $80 million Series B co-led by New Enterprise Associates and SR One to...
Pharming Appoints Kenneth Lynard Chief Financial Officer
Pharming Group has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The rare disease-focused biopharma, active...
First Oral Therapy for HER2-Mutant NSCLC Approved in China
China’s National Medical Products Administration has granted accelerated, conditional approval to Boehringer Ingelheim’s Hernexeos (zongertinib) as monotherapy for adults...